Advanced biomedical research · 2026
Guillain-Barré Syndrome (GBS) as a COVID-19 Complication: A Multicenter Study Conducted Throughout the 2-Year Pandemic.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Behnaz Ansari, Mohsen Kheradmand, Najafi Mohammad Amin, Keivan Basiri, Fariborz Khorvash, Negin Forouzandeh, Majid Ghasemi
Аннотация
BACKGROUND: Several studies have been published on the coexistence of Guillain-Barré syndrome (GBS) and COVID-19, raising the question of whether SARS-CoV-2 plays a role in GBS pathogenesis or is just a coincidence. In this research, we discuss GBS characteristics in COVID-19 patients during the pandemic.
MATERIAL AND METHODS: This cross-sectional, multi-center study was performed on patients who were hospitalized in one of two GBS referral hospitals in Isfahan Providence between March 2020 to March 2022. All confirmed GBS and COVID-19 patients with no other known risk factor for GBS and no more than 28 days of COVID-19 treatment were entered into the trial.
RESULTS: Totally, 45 patients were collected. The most prevalent EDX pattern was AIDP (57.8%). As compared to demyelinating injuries, axonal injuries were significantly more associated with lung involvement (P value: 0.022), higher GBS disability score (P value: 0.034), poorer response to treatment (P value: 0.021), higher serum inflammatory level, and older onset (P value: 0.013). The average period between the onset of COVID-19 and the onset of GBS symptoms was 18.07 ± 9.88 days. 46.3% of patients developed GBS within the first two weeks of COVID-19, a condition known as a para-infection. The axonal injury was significantly more prevalent in these individuals (P value: 0.045).
CONCLUSION: An earlier onset of neurological symptoms and para-infection conditions is associated with an increase in the frequency of axonal-type variations and, as a result, a poor prognosis. The majority of evidence in COVID-19-related GBS patients points to an autoimmune process.
MATERIAL AND METHODS: This cross-sectional, multi-center study was performed on patients who were hospitalized in one of two GBS referral hospitals in Isfahan Providence between March 2020 to March 2022. All confirmed GBS and COVID-19 patients with no other known risk factor for GBS and no more than 28 days of COVID-19 treatment were entered into the trial.
RESULTS: Totally, 45 patients were collected. The most prevalent EDX pattern was AIDP (57.8%). As compared to demyelinating injuries, axonal injuries were significantly more associated with lung involvement (P value: 0.022), higher GBS disability score (P value: 0.034), poorer response to treatment (P value: 0.021), higher serum inflammatory level, and older onset (P value: 0.013). The average period between the onset of COVID-19 and the onset of GBS symptoms was 18.07 ± 9.88 days. 46.3% of patients developed GBS within the first two weeks of COVID-19, a condition known as a para-infection. The axonal injury was significantly more prevalent in these individuals (P value: 0.045).
CONCLUSION: An earlier onset of neurological symptoms and para-infection conditions is associated with an increase in the frequency of axonal-type variations and, as a result, a poor prognosis. The majority of evidence in COVID-19-related GBS patients points to an autoimmune process.